drugset
drugset / Trial / NCT01485640

Lurasidone Extended Use Study

NCT01485640 ↗

Phase 3 Completed 162 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.

Timeline

Start
2011-06
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg Oral
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 60 mg Oral
Subject Lurasidone Small molecule 80 mg Oral

Indications

bipolar disorder schizophrenia